BNET Industries
Market Cap:$402.6M
Last Fiscal Year Sales:$12.6M
- Public
- US
Dow Jones Description
Developer of Drugs for Cancer & Infectious Disease Treatment
Number of Employees 181
Contact Information
1180 Veterans Blvd
South San Francisco, California 94080-4811
(650) 624-1100
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Rigel shares rise on RBC analyst upgrade
-
Analyst Upgrades for November 23rd
-
Rigel reports $26.7M loss in Q3
-
After-Hours Movers 9/16: ARKR Higher; CKR, RIGL, VVUS, ORCL, EK, DBRN Lower
-
Rigel Pharmaceuticals loses $29.9M in Q2
News & Analysis
Filter by
healthcare and rigel pharmaceuticals inc. - All News and Analysis
Rigel Pharma: The Importance of Knowing Your Stock
Seeking Alpha
- 2009-07-29
Stone Fox Capital submits: Last Thursday night, Rigel Pharma RIGL released disappointing results on its TASKi3 Phase 2b study on Rheumatoid Arthritis (RA). The results showed that the placebo worked basically as well as the R788 pill. Now here is where you need to understand the stock and what was...
Rigel Still on Track, And Has Pfizer Found Its Next Blockbuster?
Seeking Alpha
- 2009-01-08
Ohad Hammer submits: In the pharmaceutical industry, 2008 will probably be marked by the big pharmas’ insatiable appetite for new drugs. Threatened by fierce generic competition, the pharmaceutical giants were not only eager to pay generous acquisition premiums for marketed products, but were also willing to pay a lot of...
Rigel's Punishment May Prove Short-Sighted
Seeking Alpha
- 2008-10-31
EP Vantage submits: Rigel Pharmceuticals' RIGL shares have lost almost half their value this week since the release of fresh data from a phase II study of its lead product, R788 in rheumatoid arthritis, which considering the new information was neither overwhelmingly negative, nor entirely new, seems an overly severe...
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Johnson & Johnson |  |
| Merck | |
| Pfizer | |
| Novartis |  |
| Abbott Labs | |
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
